348 related articles for article (PubMed ID: 28317560)
21. Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.
Wong AT; Lee YC; Schwartz D; Lee A; Shao M; Han P; Choi K; Schreiber D
Int J Gynecol Cancer; 2017 Jul; 27(6):1171-1177. PubMed ID: 28574930
[TBL] [Abstract][Full Text] [Related]
22. Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.
Garg G; Yee C; Schwartz K; Mutch DG; Morris RT; Powell MA
Gynecol Oncol; 2014 May; 133(2):242-9. PubMed ID: 24561247
[TBL] [Abstract][Full Text] [Related]
23. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
24. Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J
Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
[TBL] [Abstract][Full Text] [Related]
25. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
26. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study.
Li Y; Ren H; Wang J
BMC Cancer; 2019 Jul; 19(1):697. PubMed ID: 31307426
[TBL] [Abstract][Full Text] [Related]
27. Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis.
Stokes WA; Jones BL; Schefter TE; Fisher CM
Brachytherapy; 2018; 17(1):194-200. PubMed ID: 29097136
[TBL] [Abstract][Full Text] [Related]
28. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
Temkin SM; Hellmann M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma.
Patel N; Hegarty SE; Cantrell LA; Mishra MV; Showalter TN
Brachytherapy; 2015; 14(5):606-12. PubMed ID: 26166579
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
31. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
Plante M; Stanleigh J; Renaud MC; Sebastianelli A; Grondin K; Grégoire J
Gynecol Oncol; 2017 Aug; 146(2):240-246. PubMed ID: 28577885
[TBL] [Abstract][Full Text] [Related]
32. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
Odei B; Boothe D; Suneja G; Werner TL; Gaffney DK
Am J Clin Oncol; 2018 Aug; 41(8):784-791. PubMed ID: 28121642
[TBL] [Abstract][Full Text] [Related]
36. Matched-pair Analysis for Survival Endpoints Between Women With Early-stage Uterine Carcinosarcoma and Uterine Serous Carcinoma.
Yahya JB; Zhu S; Burmeister C; Hijaz MY; Elshaikh MA
Am J Clin Oncol; 2021 Sep; 44(9):463-468. PubMed ID: 34265785
[TBL] [Abstract][Full Text] [Related]
37. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
38. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of chemotherapy and radiotherapy in the adjuvant management of uterine carcinosarcoma: a population-based analysis.
Ding L; Bi Z; Wu J; Zhu J; Yu Y; Yao HR; Liu YM
Arch Gynecol Obstet; 2023 Mar; 307(3):891-901. PubMed ID: 35708782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
